Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22634192 | 1.00 | KIF11 (0.48) | KIF11MMP2MMP9KEAP1NFE2L2 | |
| SCHEMBL367484 | 1.00 | KIF11 (0.48) | KIF11MMP2MMP9KEAP1NFE2L2 | |
| SCHEMBL1268928 | 0.96 | KIF11 (0.47) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL29422004 | 0.88 | MMP2 (0.52) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL7593135 | 0.84 | MMP9 (0.47) | MMP2MMP9TLR2 | |
| SCHEMBL17274480 | 0.83 | KIF11 (0.50) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL7603846 | 0.83 | KIF11 (0.50) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL6137134 | 0.81 | KIF11 (0.47) | KIF11 | |
| SCHEMBL6137131 | 0.81 | KIF11 (0.47) | KIF11 | |
| SCHEMBL25184422 | 0.81 | MMP2 (0.44) | KIF11MMP2MMP9TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210998-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2314609-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2113513-B1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-2081955-B1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1577323-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8404643-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20090099334-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1963362-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | KIF11 2744/4885MMP2 169/4885MMP9 184/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | KIF11 2267/4885MMP2 295/4885MMP9 150/4885 |
| US-20090099334-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | KIF11 2285/4885MMP2 255/4885MMP9 200/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | KIF11 2744/4885MMP2 169/4885MMP9 184/4885 |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | KIF11 2285/4885MMP2 255/4885MMP9 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.